NATURE’S FIRST RESPONDER™

OF OUR COMPREHENSIVE ONCOLOGY PIPELINE

haNK® and t-haNKTM
THE NANT CANCER VACCINE
Harnessing the Power of Our Immune System

NATURE’S FIRST RESPONDER™

OF OUR COMPREHENSIVE ONCOLOGY PIPELINE

haNK®, and t-haNK™
THE NANT CANCER VACCINE
Harnessing the Power of Our Immune System

Pipeline

Pipeline

Clinical Trials with Cryopreserved haNK®

Triple Negative Breast Cancer (QUILT 3.067)

Triple-Negative-Breast-Cancer

haNK® + avelumab + NCV NCT# 03387085

Merkel Cell Carcinoma (QUILT 3.063)

Merkel-Cell-Carcinoma

haNK® + avelumab + IL-15 Fusion Protein NCT# 03853317

Squamous Cell Carcinoma (QUILT 3.090)

Head_Neck-and-Squamous-Non-Small-Cell-Lung-Cancer

haNK® + avelumab + NCV NCT# 03387111

Pancreatic Cancer (QUILT 3.080)

Pancreatic-Cancer

haNK® + avelumab + NCV NCT# 03586869

Clinical Trials with Cryopreserved t-haNK™

PD-L1 High-Expressing non-Small Cell Lung Cancer/Solid Tumors

CD19_Acute-Lymphoblastic-Leukemia

PD-L1.t-haNK™ + avelumab + IL-15 Fusion Protein

CD19+ Acute Lymphoblastic Leukemia (ALL)/Diffuse Large B-Cell Lymphoma (DLBCL)

CD19_Acute-Lymphoblastic-Leukemia

CD19.t-haNK™ + avelumab + IL-15 Fusion Protein

Her2+ Breast/Gastric Cancers

AML_MDS

Her2.t-haNK™ + avelumab + IL-15 Fusion Protein

BCMA for Multiple Myeloma

Pancreatic-Cancer

BCMA.t-haNK™ + avelumab + IL-15 Fusion Protein

To learn more about the Nant Cancer Vaccine

To learn more about our clinical trials

*Reliant on Safety from Phase I dosing of haNK monotherapy and aNK or haNK in pancreatic + NCV